Speech Characteristics of Patients with Parkinson’s Disease–Does Dopaminergic Medications Have a Role?

Valiyaprambath Purushothaman Vandana1 Jeevendra Kumar Darshini1 Venkappayya Holla Vikram2 Kamble Nitish2 Pal Pramod Kumar2 Yadav Ravi2

1 Department of Speech Pathology and Audiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India
2 Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India

Abstract

Objective The present study aimed to investigate the effects of dopaminergic medication on voice, speech motor functions, and motor impairment in patients with Parkinson’s disease (PD).

Materials and Methods Twenty-five individuals (16 males and 9 females) with PD underwent comprehensive assessment of voice, speech, and motor functions in levodopa medication ON and medication OFF conditions. Age- and gender-matched healthy controls were recruited to compare speech and acoustic parameters. Multi-Dimensional Voice Program (MDVP) from Computerized Speech Laboratory (Model: 4500) was utilized for acoustic analysis of voice and the Voice Handicap Index (VHI) for the self-assessment of vocal function. Frenchay Dysarthria Assessment (FDA-2) and Unified Parkinson’s Disease Rating Scale-III (UPDRS III) were used to evaluate speech motor and motor functions, respectively.

Statistical Analysis The mean and standard deviation were used as descriptive statistics measures. Raw scores were obtained for FDA-2, DRS, VHI, MDVP parameters, and UPDRS-III in either medication condition. The Wilcoxon signed-rank test was performed to determine the statistical significance of the above measures in both genders across the medication conditions. Spearman’s rank correlation coefficient was used to determine the relationship between motor speech function and motor impairment and between VHI and MDVP parameters across both medication conditions. The interrater reliability rating was established using Cohen’s kappa.

Results An improvement in lip and laryngeal functioning was found in the medication ON over medication OFF state in both males and females with PD. A few frequency and amplitude-related measures improved in the medication-ON state over the medication-OFF state. UPDRS-III scores reduced from the OFF state to the ON state, and no change in dysarthria severity or VHI was found in either gender or medication condition. No correlation was found between speech motor function and motor...
Introduction

Parkinson’s disease (PD) is a condition associated with the degeneration of dopaminergic neurons in the basal ganglia and associated areas of the brain. Reduction in dopamine leads to several motor and nonmotor symptoms. The primary motor symptoms associated with PD include resting tremor, rigidity, akinesia (bradykinesia), and postural deficits. In addition, PD is associated with dysphagia, cognitive deficits, depression, and hypokinetic dysarthria. Hypokinetic dysarthria is characterized by hypophonia, abnormal speech rate and voice quality, imprecise consonants, and reduced pitch and loudness variation in connected speech. Voice problems may be seen in as many as 89% of individuals with PD. They have been described qualitatively as breathy, hoarse, tremulous, abnormally pitched, and having a reduced pitch range.

Individuals with PD are commonly treated with levodopa, which increases their dopamine content. It is reported to have beneficial effects on motor symptoms, but its effect on speech motor control is inconclusive. Some studies have found positive effects of levodopa on speech in terms of improved loudness, speech intelligibility, and articulation. However, other studies did not report a consistent positive outcome in speech with the intake of levodopa.

A survey of the literature reveals that there is considerable variability in the assessment procedures to investigate the speech characteristics of individuals with PD. This variability is considered in terms of only the perceptual evaluation of speech or the acoustic analysis of the vocal function or investigating specific subsystems for speech such as respiratory or vocal function before (medication-OFF) and after (medication-ON) the intake of levodopa. Although these studies contribute to the understanding of the changes in the specific speech subsystems, a comprehensive understanding of the alterations, if any, in the overall speech characteristics secondary to the intake of dopaminergic medications, is required. An investigation that employs a standardized protocol to investigate the specific speech motor functions at rest, during sustained postures, and during speech production, along with the perceptual, acoustic, and the patients’ perception of their global vocal function in the ON and OFF conditions can contribute to a holistic understanding of the effect of dopaminergic medications on the speech characteristics of these patients.

Thus, aim of this study was to investigate

1. The role of dopaminergic medication in patients with PD on vocal, speech motor function, and motor impairment by acoustic and perceptual analysis of voice.
2. The relationship between speech motor functions, vocal parameters, and motor impairment in individuals with PD in the ON and OFF conditions.

Methods

Twenty-five individuals (16 males and 9 females) with PD in the age range of 26 to 75 years were recruited from the Movement Disorder Clinic in a tertiary hospital in India. Patients with PD who were on medical management (i.e., levodopa medications, minimum dosage: 200 mg) without any other associated neurological or medical condition and who spoke any of the Indian languages with a working knowledge of Hindi or English were included in the study. Patients with dementia, apathy, psychiatric disorders, hearing impairment, or language disorders, and those aged >75 years were excluded from the study. A complete medical history and a thorough clinical examination of all the patients were done by a neurologist. Evaluation of the speech characteristics was done by an experienced speech-language pathologist (SLP). The demographic profile of individuals with PD is described in Table 1. Individuals with PD have a range of disease severities. Of the 25 participants, 7 had no speech impairment, 9 had slight speech impairment, 6 had mild speech impairment, and 3 had moderate speech impairment based on subsection 2.1 of the Unified Parkinson’s Disease Rating Scale-III (UPDRS-III), a 31-item rating scale.

| Sl no. | Gender | “n” | Mean age | Age at onset | Duration of disease |
|-------|--------|-----|----------|--------------|---------------------|
| 1.    | Males  | 16  | 57.93 ± 7.88 | 46.61 ± 8.45 | 11.30 ± 4.19        |
| 2.    | Females| 9   | 54.55 ± 10.94 | 56 ± 10.14   | 9.74 ± 4.59         |

Abbreviation: PD, Parkinson’s disease.
that evaluates behavior, mentation, mood, motor functions, and activities of daily living (ADL). None of the individuals with PD reported severe speech impairment (score of 4 on UPDRS subsection 2.1). Reports of PD-related speech impairment were relatively similar in males and females and none had received speech or language interventions prior. The mean UPDRS subsection 2.1 score was 0.79 for females and 1.09 for males, both of which are indicative of “slight” impairment.

Twenty-five volunteers (16 males [mean age = 56.87 ± 8.71] and 9 females [mean age = 54.88 ± 13.33] years) with no past history of neurological, psychiatric, or speech-language disorders were recruited as healthy controls (HC). Only speech (motor speech and voice) evaluation was done for the HC group and no follow-up testing was suggested. The participants in both the groups, that is, PD and HC groups did not differ significantly for age. All participants provided written informed consent. The study complied with the Helsinki Declaration and was approved by the institutional ethics committee.

**General Procedure**
The participants with PD were evaluated for vocal, speech, and motor impairments in two conditions: medication ON and medication OFF states. The ON state refers to the condition 1 hour after intake of the first dose of levodopa in the morning, while the OFF state refers to the condition 12 hours following the withdrawal of levodopa. Each participant with PD was tested first off and then on medication.

**Evaluation of Motor and Speech Impairments**
Motor skills were assessed using the UPDRS-III. This was administered by a neurologist at the Movement Disorders Clinic. Speech motor function was evaluated by administering the Frenchay Dysarthria Assessment-2 (FDA-2; Pam Enderby and Rebecca Palmer, 2008). It is a standardized 9-point rating scale for the evaluation of motor speech systems in the following domains: reflex, respiration, lips, tongue, soft palate, larynx, and speech intelligibility on a 5-point rating scale where 0 represents normal speech intelligibility and 6 poor speech intelligibility. The speech samples recorded in both medication conditions were randomized, anonymized, and subjected to perceptual analysis by three SLPs. They were aware of the PD diagnosis of the patients but were blinded to the states (Medication-ON and Medication-OFF) in which the samples were recorded.

**Self-Assessment of Global Vocal Function**
Patients were asked to evaluate their vocal function by the administration of Voice Handicap Index-10 (VHI-10,17 which is a 10-item questionnaire evaluating the patients’ self-perception of vocal difficulties across three domains: (a) functional, (b) physical, and (c) emotional on a 5-point rating scale, that is, 0—never and 4—always. The maximum score is 40, and a score >11 is considered abnormal.

**Acoustic Analysis of Voice**
The acoustic analysis of voice was performed by recording the voice onto the Multi-Dimensional Voice Program (MDVP) module on the Computerized Speech Laboratory (CSL; Model: 4500) for analysis. Each patient was seated in the upright position and instructed to phonate /a/ at a pitch and loudness level comfortable for each of them for a minimum duration of 3 second. For acoustic analysis, the sustained vowel /a/ was selected as it enabled the understanding of laryngeal function primarily by reducing the effect of coarticulation that would otherwise be a factor in connected speech. Further, this task requires limited participant training. To control for the phonatory onset and offset, only the midsection of the vowel was considered for analysis. The recording of the speech signal was done by placing the microphone 10 cm away from the participant’s lips. Acoustic parameters considered for analysis were the average fundamental frequency (F0) in Hertz, period to period variability in pitch-absolute jitter (µs), frequency tremor intensity index in percent(FTRI%), period to period variability in amplitude-shimmer (dB), and soft phonation index (SPI). The recording was performed in a well-lit and sound-proof room.

**Data Analysis**
Descriptive statistics were used to determine the mean and standard deviation (SD) for the values obtained in the FDA-2, DRS, VHI, MDVP parameters, and UPDRS-III in either medication condition. To determine the statistical significance of the above measures in both genders across the medication conditions, Wilcoxon signed-rank test was performed. To determine the relationship between motor speech function and motor impairment and between VHI and MDVP parameters across both medication conditions, Wilcoxon signed-rank test was performed. To determine the interrater reliability rating was established using Cohen’s kappa. Statistical analysis was performed using SPSS 20.0. Level of Statistical significance was set at p < 0.05.

**Results**
**Comparison of Acoustic Parameters between HC and Individuals with PD**
There was a significant difference between HC and PD with respect to lip function, laryngeal function, and speech intelligibility (p < 0.05) in the FDA-2. The acoustic parameters of F0 (Hz) for males and SPI for females were also significantly different (p < 0.05) between the two groups.
Comparison of Speech Motor Function, Severity of Dysarthria, and Motor Impairment between Medication ON and OFF Conditions

The mean and SD values for the individual subsections of FDA-2, DRS, and UPDRS-III across the two medication conditions and their p-values are shown in Table 2. A significant difference in the lip and laryngeal functions in FDA-2 and UPDRS-III was found in both males and females between the two medication conditions. However, there was no significant difference in the severity of dysarthria between the two medication conditions in either male or female patients.

Comparison of Acoustic Parameters of Voice and Patients’ Self-Assessment of Vocal Function between Medication ON and OFF Conditions

The mean and SD values for the acoustic parameters of voice and the VHI prior (medication-OFF) and after (medication-ON) the intake of medication for both males and females are shown in Table 3. A significant difference was found for the following acoustic parameters of voice for males between the two medication conditions: F0 (Hz), FTRI (%), and vAm (%) (p < 0.05). A significant improvement in frequency parameters mainly the fundamental frequency (p < 0.05) that represents the number of times the vocal cords vibrate per second was noticed in medication-ON state for males. The tremor parameter of frequency (i.e., FTRI%) and amplitude parameter of peak amplitude variation (vAm%) reduced from the OFF state to the ON state. There was no significant difference in the acoustic parameters of voice in females between the two medication conditions.

Spearman’s correlation coefficient for evaluating the relationship between motor speech function and motor impairment, as well as acoustic parameters of voice with VHI in both males and females in the two medication conditions, revealed no correlation between any of these parameters. The interrater reliability for the speech intelligibility ratings in either medication condition for both males and females was determined using Cohen’s kappa coefficient. Substantial to near perfect agreement (0.73–0.91) was established for the intelligibility ratings by the three raters in either medication condition for both genders.

Discussion

The present study aimed to evaluate the voice, motor speech, and motor functions of individuals with PD in the ON and OFF states. Gender significantly influences voice and speech,18–20 hence, males and females were evaluated separately. HC and patients with PD differed significantly for lip and laryngeal functioning and with reference to the acoustic parameters; there was a difference only for F0 in males and SPI in females. The difference between the two groups for only specific speech subsystem functioning can be due to the lack of significant

Table 2 Mean, SD, and p-values for the speech motor function, severity of dysarthria and motor impairment between the two medication conditions in males (M) and females (F)

|                     | Medication-OFF | Medication-ON | p-Value |
|---------------------|----------------|---------------|---------|
| Reflexes (M)        | 8.02           | 8.15          | 0.04*   |
| (F)                 | 8.32           | 8.32          | 1.00    |
| Respiration(M)      | 7.43           | 7.62          | 0.06    |
| (F)                 | 7.55           | 7.55          | 1.00    |
| Lips (M)            | 7.34           | 7.66          | 0.01*   |
| (F)                 | 7.21           | 7.83          | 0.01*   |
| Palate (M)          | 8.61           | 8.68          | 0.49    |
| (F)                 | 9.00           | 9.00          | 1.00    |
| Laryngeal (M)       | 6.15           | 6.56          | 0.01*   |
| (F)                 | 6.02           | 6.52          | 0.01*   |
| Tongue (M)          | 7.24           | 7.37          | 0.91    |
| (F)                 | 7.61           | 7.67          | 0.31    |
| Intelligibility(M)  | 7.00           | 7.21          | 0.75    |
| (F)                 | 7.16           | 7.27          | 0.36    |
| DRS(M)              | 2.93           | 2.81          | 0.65    |
| (F)                 | 2.77           | 2.77          | 1.00    |
| UPDRS-III(M)        | 48.38          | 18.81         | 0.01*   |
| (F)                 | 39.80          | 20.43         | 0.05*   |

Abbreviations: DRS, Dysarthria Rating of Severity; SD, standard deviation; UPDRS-III, Unified Parkinson’s Disease Rating Scale-III.
*p < 0.05.
speech impairment in our PD cohort, which would otherwise have affected the other speech subsystems as well. An increase in F0 in males with PD is consistent with the findings of the studies revealing the same in those in the early and later stages of PD. An increase in SPI in women with PD is suggestive of incomplete glottal closure and loose adduction of vocal folds compared with HC.

Lip and laryngeal functions significantly improved in the medication-ON over the medication-OFF state in both males and females with PD. Rusz et al reported improved pitch flexibility and lip and laryngeal function in the ON state. They ascribed this to improvement in postural tension, thus improving the range of oromotor and laryngeal movements. Labial function improved from the OFF state to the ON state. This finding was similar to that of Lechien et al, who reported that levodopa significantly improved lip strength, frequency of labial movement, and labial motility. Pinto et al also indicated that levodopa treatment decreased nonspeech labial rigidity and increased the amplitude of labial movements. A trend toward a significant difference in tongue function was observed for males between the two medication states. A reduction in rigidity and bradykinesia in the ON state can explain this difference.

The UPDRS scores showed significant improvement following intake of levodopa, whereas the speech intelligibility and severity of dysarthria remained the same (Table 2). There was no correlation between any of the acoustic parameters and UPDRS. Several previous studies have found stable or poorly responsive speech and phonatory measurements, despite levodopa-related motor changes from OFF to ON states. This is in contrast to the significant correlations found between acoustic findings and both the ADL and motor portions of the UPDRS by Silbergleit et al. Levodopa treatment has had mixed and contradictory results with respect to changes in speech impairments in PD. Some studies reported a slight improvement in intonation, vowel articulation, and speech intelligibility, while other studies showed no significant effect of levodopa. Increased speech volume and improved speech intelligibility were noted in some patients, while no improvements were seen in others by Fabbri et al. Ma et al reported an inconsistent effect of dopaminergic medication on speech prosody. They speculated about the role of nondopaminergic mechanisms in improving speech prosody. In contrast to reports that showed no changes in F0 SD or jitter to levodopa intake, Pinho et al reported that the use of levodopa improves vocal parameters such as fundamental frequency (F0) and jitter, but not vocal intensity. The results of our study also indicate similar findings with few acoustic voice parameters such as F0, FTRI (IRB%), and vAm improvement, but other parameters remained stable. A trend for voice improvement was noticed following the treatment with levodopa. This was with respect to pitch and intensity variability and articulation. Inconsistency across studies may be due to participant-related variances, intake of other medications, and differences in dysarthria severity.

| Table 3 Mean, SD, and p-values for the acoustic parameters of voice and patients’ self-assessment of vocal function (VHI) between the medication ON and OFF conditions across males and females |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Medication-OFF  | Medication-ON   |                 |                 |                 |                 |
|                 | Mean            | SD              | Mean            | SD              | p-Value         |                 |
| F0 (Hz) (M)     | 141.5           | 43.05           | 149.9           | 38.9            | 0.04*           |                 |
| (F)             | 183.73          | 32.96           | 180.9           | 48.21           | 0.51            |                 |
| Jitter(µs) (M)  | 109.8           | 77.91           | 97.05           | 100.05          | 0.06            |                 |
| (F)             | 65.15           | 56.15           | 62.74           | 78.54           | 0.31            |                 |
| Shimmer(dB) (M)| 0.57            | 0.30            | 0.45            | 0.24            | 0.20            |                 |
| (F)             | 0.38            | 0.24            | 0.39            | 0.20            | 0.62            |                 |
| FTRI(%) (M)     | 3.09            | 9.8             | 0.40            | 0.47            | 0.01*           |                 |
| (F)             | 0.37            | 0.33            | 0.46            | 0.46            | 0.57            |                 |
| SPI (M)         | 16.98           | 5.62            | 17.18           | 6.55            | 0.87            |                 |
| (F)             | 16.59           | 11.19           | 13.79           | 4.69            | 0.67            |                 |
| vF0 (M)         | 2.09            | 1.35            | 1.79            | 1.89            | 0.05            |                 |
| (F)             | 1.67            | 0.76            | 2.89            | 4.07            | 0.95            |                 |
| vAm (M)         | 10.87           | 5.71            | 7.76            | 2.99            | 0.03*           |                 |
| (F)             | 10.16           | 4.78            | 9.19            | 3.71            | 0.59            |                 |
| VHI (M)         | 25.68           | 7.04            | 22.81           | 7.20            | 0.43            |                 |
| (F)             | 25.33           | 6.02            | 23.77           | 2.58            | 0.37            |                 |

Abbreviations: F0, average fundamental frequency; FTRI, Frequency Tremor Intensity Index; Jitter, frequency perturbation; SD, standard deviation; Shimmer, amplitude perturbation; SPI, soft phonation index; vAm, variation in amplitude; vF0, variation in F0; VHI, Voice Handicap Index.

*p-Values are significant at 0.05.
There may have been some dissociation between the influence of levodopa on motor symptoms and certain speech characteristics in patients with PD. The differences in the response of motor and certain speech characteristics may be due to the presence of both dopaminergic and nondopaminergic lesions associated with speech production in PD.\textsuperscript{32–35} The presence of a unique levodopa dose-based response curve for individual symptom in PD might be another possible explanation.\textsuperscript{36} This suggests that speech symptoms with a flat dose–response curve may be underdosed; hence, it may not be considered that these are resistant to levodopa. The need to conduct systematic dosage increase studies on speech symptoms to explore this was emphasized in their study. Alternatively, other studies identify nondopaminergic mechanisms such as defects in vocal loudness perception and altered sensory processing as the underlying pathophysiological mechanisms of voice and speech impairments.\textsuperscript{36–38}

No correlation between VHI and a measure of voice disability with acoustic voice tremor measures was found. This finding is not unexpected, since it is challenging to compare acoustic measures that are objective in nature to the self-perceived measure of a voice problem. This is because VHI varies for each patient depending on their social connections, family interactions, job, and personality.\textsuperscript{39} There was no change in the VHI between the ON and OFF states in our study. Cushnie-Sparrow et al\textsuperscript{13} speculated that irrespective of the order of withdrawal of medication, the exacerbated symptoms of PD in the OFF state may lead to mood fluctuations and physical distress that can possibly affect the speech and voice in these individuals in the ON state as well.

**Conclusion**

The purpose of this study was to examine the acoustic, perceptual, and motor characteristics of individuals with PD before and after taking dopaminergic medication. The PD patients’ improvement in motor skills was predominant compared with minor improvements in measures of voice and articulation, when examined in their OFF to ON states. No significant correlations were found between PD disease duration and any of the parameters. The results of this study suggest the effectiveness of nonpharmacological treatments such as speech therapy for the management of speech impairments in PD.

Counterbalancing the order of medication states would strengthen the findings of this study. Studies should also be conducted to examine changes in speech symptoms across a range of levodopa doses. The PD subjects studied had a wide age range and disease characteristics, and none of the patients showed severe speech impairments. Differences between ON and OFF states tend to be higher when there is severe speech impairment, suggestive of a ceiling effect. A similar study with individuals with PD with severe speech intelligibility should be performed to answer the research questions posed. Analysis of individual patient data may shed more light on the causes of speech variability.

**Authors’ Contributions**

V.P.V. was involved in conception and design, acquisition of data, drafting of the article or critical revision of the manuscript for important intellectual content; J.K.D. was involved in acquisition of data, analysis and interpretation of data, drafting of the article, and critical revision of the manuscript; V.H.V. was involved in acquisition of data and critical revision of the manuscript; K.N. was involved in data interpretation and critical revision of the manuscript for important intellectual content; P.P.K. was involved in critical revision of the manuscript for intellectual content; Y.R. was involved in critical revision of the manuscript for intellectual content. All authors read and approved the final manuscript.

**Ethics Approval**

The study is in compliance with the Declaration of Helsinki and was approved by the Research Ethics Committees of NIMHANS, Bengaluru.

**Funding**

None.

**Conflict of Interest**

None declared.

**Acknowledgments**

The authors are grateful to the participants for their participation in the study.

**References**

1. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson’s disease puzzle. Nat Med 2010;16(06):653–661
2. De Letter M, Santens P, Estercam I, et al. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson’s disease as perceived by professional listeners. J Commun Disord 2007b38:187–196
3. Rusz J, Hlavnička T, Šykalová T, et al. Quantitative assessment of motor speech abnormalities in idiopathic rapid eye movement sleep behaviour disorder. Sleep Med 2016;19:141–147
4. Fahn S, Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord 2015;30(01):1–3
5. Spencer KA, Morgan KW, Blond E. Dopaminergic medication effects on the speech of individuals with Parkinson’s disease. J Med Speech-Lang Pathol 2009;17:125–144
6. Goberman AM, Coelho C. Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy. NeuroRehabilitation 2002;17(03):237–246
7. Skodda S, Grönhart W, Schlegel U. Intonation and speech rate in Parkinson’s disease: general and dynamic aspects and responsiveness to levodopa admission. J Voice 2011;25(04):e199–e205
8. Okada Y, Murata M, Toda T. Effects of levodopa on vowel articulation in patients with Parkinson’s disease. Kobe J Med Sci 2015;61(05):E144–E154
9. De Letter M, Santens P, De Bodt M, Van Maele G, Van Borsel J, Boon P. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson’s disease. Clin Neurol Neurosurg 2007a109(06):495–500
10. Ho AK, Bradshaw JL, lansek R. For better or worse: the effect of levodopa on speech in Parkinson’s disease. Mov Disord 2008;23 (04):574–580
Speech Characteristics of Patients with PD  
Vandana et al.

11 Plowman-Prine EK, Okun MS, Sapienza CM, et al. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. NeuroRehabilitation 2009;24(02):131–144

12 Elfmarková N, Gajoš M, Mračková M, Mekyska J, Míkl M, Rektorová I. Impact of Parkinson’s disease and levodopa on resting state functional connectivity related to speech prosody control. Parkinsonism Relat Disord 2016;22(Suppl 1):S52–S55

13 Cuschnie-Sparrow D, Adams S, Abeysekera A, Pieterman M, Gilmore G, Jog M. Voice quality severity and responsiveness to levodopa in Parkinson’s disease. J Commun Disord 2018;76(76):1–10

14 Sanabria J, Ruiz PG, Gutierrez R, et al. The effect of levodopa on vocal function in Parkinson’s disease. Clin Neuropharmacol 2001;24(02):99–102

15 Enderby PM. 1983Frenchay Dysarthria Assessment. College-Hill Press. ISBN 0–933014–82–1

16 Yorkston KM, Beukelman DR, Strand EA, Bell KR. Management of Motor Speech Disorders in Children and Adults. Austin, Texas: Pro-Ed; 1999

17 Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the voice handicap index-10. Laryngoscope 2004;114(09):1549–1556

18 Solomon NP, Hixon TJ. Speech breathing in Parkinson’s disease. J Speech Hear Res 1993;36(02):294–310

19 Olsen C. Sex differences in English intonation observed in female impersonation. Toronto Papers of the Speech and Voice Society 1981;2:30–49

20 Titze IR. Physiologic and acoustic differences between male and female voices. J Acoust Soc Am 1989;85(04):1699–1707

21 Holmes RJ, Oates JM, Phyland DJ, Hughes AJ. Voice characteristics in the progression of Parkinson’s disease. Int J Lang Commun Disord 2000;35(03):407–418

22 Midi I, Dogan M, Koseoglu M, Can G, Sehitoglu MA, Gunal DI. Voice abnormalities and their relation with motor dysfunction in Parkinson’s disease. Acta Neurol Scand 2008;117(01):26–34

23 Rusz J, Cmejla R, Růžičková H, et al. Evaluation of speech impairment in early stages of Parkinson’s disease: a prospective study with the role of pharmacotherapy. J Neural Transm (Vienna) 2013;120(02):319–329

24 Lechien JR, Blecic S, Ghosez Y, Huet K, Harmenegies B, Saussez S. Voice quality and orofacial strength as outcome of levodopa effectiveness in patients with early idiopathic Parkinson disease: a preliminary report. J Voice 2019;33(05):716–720

25 Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Azou P. Treatments for dysarthria in Parkinson’s disease. Lancet Neurol 2004;3(09):547–556

26 Sewall GK, Jiang J, Ford CN. Clinical evaluation of Parkinson’s-related dysphonia. Laryngoscope 2006;116(10):1740–1744

27 Lazarus JP, Vibha D, Handa KK, et al. A study of voice profiles and acoustic signs in patients with Parkinson’s disease in North India. J Clin Neurosci 2012;19(08):1125–1129

28 Skodda S, Visser W, Schlegel U. Short- and long-term dopaminergic effects on dysarthria in early Parkinson’s disease. J Neural Transm (Vienna) 2010;117(02):197–205

29 Silberglik AK, LeWitt PA, Peterson EL, Gardner GM. Quantitative analysis of voice in Parkinson disease compared to motor performance: a pilot study. J Parkinsons Dis 2015;5(03):517–524

30 Rusz J, Tykalová T, Klémplíř J, Čmejla R, Růžička E. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson’s disease: longitudinal follow-up study on previously untreated patients. J Neural Transm (Vienna) 2016;123(04):379–387

31 Fabbri M, Guimarães I, Cardoso R, et al. Speech and voice response to a levodopa challenge in late-stage Parkinson’s disease. Front Neurol 2017;8:432

32 Ma A, Lau KK, Thyagarajan D. Voice changes in Parkinson’s disease: what are they telling us? J Clin Neurosci 2020;72:1–7

33 Pinho P, Monteiro L, Soares MFP, Tourinho L, Melo A, Nóbrega AC. Impact of levodopa treatment in the voice pattern of Parkinson’s disease patients: a systematic review and meta-analysis. CoDAS 2018;30(05):e20170200

34 D’Alatri L, Paludetti G, Contarino MF, Galla S, Marchese MR, Bentivoglio AR. Effects of bilateral subthalamic nucleus stimulation and medication on parkinsonian speech impairment. J Voice 2008;22(03):365–372

35 Goberman AM. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson disease. Med Sci Monit 2005;11(03):CR109–CR116

36 Nonnekes J, Timmer MMH, de Vries NM, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson’s disease. Mov Disord 2016;31(11):1602–1609

37 Friedman JH. Misperceptions and Parkinson’s disease. J Neurol Sci 2017;374:42–46

38 Brajot FX, Shiller DM, Gracco VL. Autophonic loudness perception in Parkinson’s disease. J Acoust Soc Am 2016;139(03):1364–1371

39 Wheeler KM, Collins SP, Sapienza CM. The relationship between VHI scores and specific acoustic measures of mildly disordered voice production. J Voice 2006;20(02):308–317